Smoking, Headaches And Allergies: Rx Pipeline Drugs May Impact OTCs
This article was originally published in The Pink Sheet Daily
Executive Summary
Rx products which could have implications for OTC markets include Schering-Merck’s Claritin/Singulair combination and new Schering Clarinex formulations. Pfizer’s nicotine replacement therapy varenicline is in Phase III; Relpax and Celebrex gain market share in migraine, arthritis markets, respectively.